1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Guangzheng Eye Hospital Group Co., Ltd. Class A

Guangzheng Eye Hospital Group Co., Ltd. Class A

SSZSE:002524
3.75
CNY
+0.04
(+1.08%)
1.71BMarket Cap
Guangzheng Eye Hospital Group Co., Ltd. Class A
SZSE:002524
(Shenzhen Stock Exchange)

Recent

price

3.75

P/E

ratio

- -

div

yld

0.54%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.05
1.01
1.14
0.97
1.21
0.85
1.03
1.02
2.36
2.48
1.73
1.98
1.47
2.32
1.74
1.82
- -
Revenue per Share
0.06
0.06
0.07
- -
-0.17
0.01
0.01
0.01
-0.15
0.14
0.08
0.07
-0.15
0.02
-0.34
-0.04
- -
Basic EPS, GAAP
-0.12
-0.3
-0.38
-0.28
-0.07
0.06
-0.02
0.13
0.55
0.07
0.17
0.18
0.16
0.03
0.08
0.2
- -
Free Cash Flow per Basic Share
0.02
0.02
0.03
0.05
0.07
0.06
0.14
0.09
0.09
0.14
0.09
0.03
0.02
0.03
0.03
0.03
0.02
Dividend per Share
1.14
1.19
1.24
1.69
1.52
1.55
1.46
1.52
1.61
1.72
0.63
0.66
0.53
0.55
0.22
0.19
0.22
Book Value per Share
1.06
1.02
0.93
1.29
0.81
0.89
0.8
0.87
0.03
0.42
-0.56
-0.45
-0.28
-0.26
-0.3
-0.33
-0.3
Tangible Book Value per Share
363
420
410
520
516
650
484
542
499
519
532
528
521
463
514
487
482
Basic Weighted Avg Shares
382
426
466
505
626
555
499
554
1,175
1,285
921
1,044
767
1,075
893
885
- -
Sales/Revenue/Turnover
7.25
7.19
7.45
4.18
-3.92
5.32
-1.77
0.85
8.57
13.63
4.19
0.07
-11.72
4.49
-0.06
3.58
- -
Operating Margin (%)
6
9
14
28
55
77
82
84
98
98
63
106
100
100
96
92
- -
Depreciation Expense
22
24
28
2
-88
6
5
5
-75
73
43
37
-78
9
-175
-19
- -
Net Income, GAAP
18.8
16.59
16.16
10.94
- -
13.29
40.26
50.03
- -
27.33
30.15
18.9
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.84
5.71
5.98
0.31
-14
1.17
0.97
0.98
-6.37
5.66
4.62
3.54
-10.19
0.86
-19.56
-2.2
- -
Profit Margin (%)
407
324
150
448
-47
10
-220
-187
-343
-6
-552
-640
-545
-439
-416
-473
-418
Working Capital
50
50
45
435
269
253
184
110
316
160
745
506
449
494
439
339
365
LT Debt
468
489
513
1,035
1,037
1,048
809
856
1,176
1,059
337
341
275
286
117
100
112
Total Equity
5.31
3.53
3.03
-1.04
- -
0.07
0.27
0.65
- -
9.79
2.59
3.3
- -
- -
- -
- -
- -
Return on Invested Capital (%)
6.88
5.05
5.5
1.61
- -
0.9
1.63
1.41
- -
0.66
5.36
5.49
- -
- -
- -
- -
- -
Return on Capital (%)
7.46
5.09
5.56
0.23
-10.84
0.84
0.64
0.72
-9.49
8.55
7.02
11.1
-25.49
3.33
-88.22
-18.7
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
412
431
374
LT Borrowings
2
2
23
LT Finance Leases
336
363
343
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
515
515
515
Market Capitalization
2,123
2,283
1,706

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
258
239
234
Cash, Cash Equivalents & STI
49
46
50
Accounts Receivable, Net
96
86
86
Inventories
28
31
25
Total Current Liabilities
731
714
652
Payables & Accruals
- -
- -
- -
ST Debt
412
431
374
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-14.55%
-17.55%
-14.65%
Free Cash Flow
-31.05%
41.85%
120.89%
Net Income, GAAP
-424.64%
-502.58%
-88.84%
Sales/Revenue/Turnover
10.32%
1.83%
-0.86%
Total Cash Common Dividend
0.63%
-13.15%
-7.23%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
282
217
194
893
2025
208
228
- -
222
885
2026
187
203
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
0.04
-0.04
-0.3
-0.34
2025
- -
- -
- -
-0.04
-0.04
2026
-0.01
0.04
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.03
2025
0.01
0.01
- -
0.01
0.03
2026
0.01
0.01
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Guangzheng Eye Hospital Group Co., Ltd. operates primarily in the ophthalmology medical services sector in China. Founded in 2001 and headquartered in Urumqi, Xinjiang, the company manages 13 eye hospitals and 1 optometry clinic across major Chinese cities including Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, and others. Its core products and services encompass comprehensive ophthalmic medical services such as diagnosis and treatment of various eye diseases, medical optometry services, investment in and operation of eye hospitals, and research in ophthalmic medical technology. Additionally, the company engages in steel structure construction and sales, natural gas transportation and sales, leasing of properties, and operation of gas stations. It provides light steel, heavy steel, multi-high-rise steel, and long-span steel structures including structural steel engineering and bridge construction. Recently, Guangzheng Eye Hospital Group has completed the acquisition of the remaining 49% stake in Shanghai New Vision Eye Hospital Investment Co., Ltd., expanding its footprint in ophthalmic medical services. The company also restructured its natural gas unit by transferring its 100% stake in Xintianshan Gas to its wholly owned subsidiary, Bright Bazhou. It continues to enhance medical services through advanced technology collaborations, such as the partnership with Jabra to upgrade audiovisual equipment for improved diagnosis and communication quality in its hospitals. These moves reflect Guangzheng's strategic expansion and integration in both its medical services and energy sectors. The company targets patients requiring specialized eye care and related medical services, serving urban populations in China. It operates under several business segments including ophthalmology medical services, steel structure engineering, and energy. Over its history, Guangzheng Eye Hospital Group has received multiple honors for medical quality and service capability and maintains a diverse portfolio with substantial geographic reach within China. Its combination of healthcare services with industrial operations in construction and energy distinguishes its business model in the Chinese market.